Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma
continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the …

Introduction: The therapeutic landscape of metastatic urothelial carcinoma (mUC) becomes
increasingly dense: standard therapy remains cisplatin-based chemotherapy, followed by …

Urothelial carcinoma is a common malignancy that affects the urinary system, with bladder
cancer being the most prevalent form. Although the management of early-stage disease has …

Enfortumab vedotin (EV) is a novel antibody–drug conjugate that is the first in class to be
FDA-approved for use in patients with treatment-refractory urothelial cancer. Enfortumab is …

Background Enfortumab vedotin (EV) is a novel antibody‐drug conjugate approved for
advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer …

The treatment landscape for locally advanced or metastatic urothelial carcinoma has
broadened significantly over recent years. New therapeutic options include immunotherapy …

Background/Aim: This study retrospectively investigated the impact of enfortumab vedotin
(EV) monotherapy on the oncological outcome, safety profile, and health-related quality of …

Background Treatment options for patients with urothelial cancer (UC) refractory to platinum
and immunotherapy are limited and survival is short. Enfortumab vedotin (EV) is a …

Enfortumab vedotin (EV) is the first antibody–drug conjugate approved for locally advanced
or metastatic urothelial cancers (la/mUCs), a disease group historically associated with …

Locally advanced or metastatic urothelial cancer is an aggressive form of cancer with high
recurrence rates and low survival. Nectin-4 is a cell adhesion molecule commonly …